Drug
VY Aadc02
VY Aadc02: highest development phase Phase 1, developed by Neurocrine Biosciences. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Neurocrine Biosciences
Trials
| Drug | Phase | Indication |
|---|---|---|
| VY-AADC02 NCT03562494 | Phase 1 | Parkinson's Disease |
Latest
No recent events.
Follow VY Aadc02 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.